{"title":"激光原位角膜磨镶术后的后房型人工晶体植入术。","authors":"Kazutaka Kamiya, Kimiya Shimizu, Akihito Igarashi, Yoshihiro Kitazawa, Takashi Kojima, Tomoaki Nakamura, Kazuo Ichikawa, Sachiko Fukuoka, Kahoko Fujimoto","doi":"10.1186/s40662-022-00282-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To assess the multicenter outcomes of posterior chamber phakic intraocular lens implantation with a central hole (EVO-ICL, STAAR Surgical) for patients undergoing previous laser in situ keratomileusis (LASIK).</p><p><strong>Methods: </strong>This case series enrolled 31 eyes of 21 consecutive patients undergoing EVO-ICL implantation to correct residual refractive errors after LASIK at 7 nationwide major surgical sites. We investigated safety, efficacy, predictability, stability, and adverse events at 1 week, 1, 3, and 6 months postoperatively, and at the final visit.</p><p><strong>Results: </strong>The mean observation period was 1.6 ± 1.8 years. Uncorrected and corrected visual acuities were - 0.14 ± 0.11 and - 0.22 ± 0.09 logMAR at 6 months postoperatively. At 6 months postoperatively, 81% and 100% of eyes were within ± 0.5 D and ± 1.0 D, respectively, of the targeted correction. We found neither significant manifest refraction changes of 0.05 ± 0.38 D from 1 week to 6 months nor apparent intraoperative or postoperative complications in any case.</p><p><strong>Conclusions: </strong>Our multicenter study confirmed that the EVO-ICL provided good outcomes in safety, efficacy, predictability, and stability, even in post-LASIK eyes. Therefore, EVO-ICL implantation may be a viable surgical option, even for correcting residual refractive errors after LASIK. Trial registration University Hospital Medical Information Network Clinical Trial Registry (000045295).</p>","PeriodicalId":50569,"journal":{"name":"Distributed Computing","volume":"1 1","pages":"15"},"PeriodicalIF":1.3000,"publicationDate":"2022-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008970/pdf/","citationCount":"0","resultStr":"{\"title\":\"Posterior chamber phakic intraocular lens implantation after laser in situ keratomileusis.\",\"authors\":\"Kazutaka Kamiya, Kimiya Shimizu, Akihito Igarashi, Yoshihiro Kitazawa, Takashi Kojima, Tomoaki Nakamura, Kazuo Ichikawa, Sachiko Fukuoka, Kahoko Fujimoto\",\"doi\":\"10.1186/s40662-022-00282-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>To assess the multicenter outcomes of posterior chamber phakic intraocular lens implantation with a central hole (EVO-ICL, STAAR Surgical) for patients undergoing previous laser in situ keratomileusis (LASIK).</p><p><strong>Methods: </strong>This case series enrolled 31 eyes of 21 consecutive patients undergoing EVO-ICL implantation to correct residual refractive errors after LASIK at 7 nationwide major surgical sites. We investigated safety, efficacy, predictability, stability, and adverse events at 1 week, 1, 3, and 6 months postoperatively, and at the final visit.</p><p><strong>Results: </strong>The mean observation period was 1.6 ± 1.8 years. Uncorrected and corrected visual acuities were - 0.14 ± 0.11 and - 0.22 ± 0.09 logMAR at 6 months postoperatively. At 6 months postoperatively, 81% and 100% of eyes were within ± 0.5 D and ± 1.0 D, respectively, of the targeted correction. We found neither significant manifest refraction changes of 0.05 ± 0.38 D from 1 week to 6 months nor apparent intraoperative or postoperative complications in any case.</p><p><strong>Conclusions: </strong>Our multicenter study confirmed that the EVO-ICL provided good outcomes in safety, efficacy, predictability, and stability, even in post-LASIK eyes. Therefore, EVO-ICL implantation may be a viable surgical option, even for correcting residual refractive errors after LASIK. Trial registration University Hospital Medical Information Network Clinical Trial Registry (000045295).</p>\",\"PeriodicalId\":50569,\"journal\":{\"name\":\"Distributed Computing\",\"volume\":\"1 1\",\"pages\":\"15\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2022-04-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008970/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Distributed Computing\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s40662-022-00282-6\",\"RegionNum\":4,\"RegionCategory\":\"计算机科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"COMPUTER SCIENCE, THEORY & METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Distributed Computing","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40662-022-00282-6","RegionNum":4,"RegionCategory":"计算机科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"COMPUTER SCIENCE, THEORY & METHODS","Score":null,"Total":0}
Posterior chamber phakic intraocular lens implantation after laser in situ keratomileusis.
Background: To assess the multicenter outcomes of posterior chamber phakic intraocular lens implantation with a central hole (EVO-ICL, STAAR Surgical) for patients undergoing previous laser in situ keratomileusis (LASIK).
Methods: This case series enrolled 31 eyes of 21 consecutive patients undergoing EVO-ICL implantation to correct residual refractive errors after LASIK at 7 nationwide major surgical sites. We investigated safety, efficacy, predictability, stability, and adverse events at 1 week, 1, 3, and 6 months postoperatively, and at the final visit.
Results: The mean observation period was 1.6 ± 1.8 years. Uncorrected and corrected visual acuities were - 0.14 ± 0.11 and - 0.22 ± 0.09 logMAR at 6 months postoperatively. At 6 months postoperatively, 81% and 100% of eyes were within ± 0.5 D and ± 1.0 D, respectively, of the targeted correction. We found neither significant manifest refraction changes of 0.05 ± 0.38 D from 1 week to 6 months nor apparent intraoperative or postoperative complications in any case.
Conclusions: Our multicenter study confirmed that the EVO-ICL provided good outcomes in safety, efficacy, predictability, and stability, even in post-LASIK eyes. Therefore, EVO-ICL implantation may be a viable surgical option, even for correcting residual refractive errors after LASIK. Trial registration University Hospital Medical Information Network Clinical Trial Registry (000045295).
期刊介绍：
The international journal Distributed Computing provides a forum for original and significant contributions to the theory, design, specification and implementation of distributed systems.
Topics covered by the journal include but are not limited to:
design and analysis of distributed algorithms;
multiprocessor and multi-core architectures and algorithms;
synchronization protocols and concurrent programming;
distributed operating systems and middleware;
fault-tolerance, reliability and availability;
architectures and protocols for communication networks and peer-to-peer systems;
security in distributed computing, cryptographic protocols;
mobile, sensor, and ad hoc networks;
internet applications;
concurrency theory;
specification, semantics, verification, and testing of distributed systems.
In general, only original papers will be considered. By virtue of submitting a manuscript to the journal, the authors attest that it has not been published or submitted simultaneously for publication elsewhere. However, papers previously presented in conference proceedings may be submitted in enhanced form. If a paper has appeared previously, in any form, the authors must clearly indicate this and provide an account of the differences between the previously appeared form and the submission.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
